{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:21:50Z","timestamp":1766269310655,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ucl.2019.09.007","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T12:40:51Z","timestamp":1574167251000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Salvage Therapy Using Bacillus Calmette-Gu\u00e9rin Derivatives or Single Agent Chemotherapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Christopher R.","family":"Haas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.ucl.2019.09.007_bib1","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3 Pt 1","key":"10.1016\/j.ucl.2019.09.007_bib2","first-page":"685","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.007_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous Bacille Calmette-Guerin failure pattern on subsequent response to Bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.007_bib4","first-page":"1021","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.ucl.2019.09.007_bib5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1021\/tx3002065","article-title":"A\u00a0new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase","volume":"25","author":"Paz","year":"2012","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.007_bib6","first-page":"90","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.007_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.007_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.007_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.007_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.007_bib11","first-page":"761","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"8","key":"10.1016\/j.ucl.2019.09.007_bib12","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"issue":"18","key":"10.1016\/j.ucl.2019.09.007_bib13","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ucl.2019.09.007_bib14","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in Bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2019.09.007_bib15","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus Bacille Calmette-Guerin after initial Bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.007_bib16","first-page":"1200","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"19","key":"10.1016\/j.ucl.2019.09.007_bib17","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.007_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","article-title":"Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy","volume":"75","author":"Laudano","year":"2010","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.007_bib19","first-page":"1633","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.007_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.urology.2017.01.018","article-title":"Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous bacillus Calmette-Guerin Therapy","volume":"103","author":"Robins","year":"2017","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.007_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00294019","article-title":"Induction of controlled prostatic tissue necrosis by Bacille Calmette-Guerin derivatives","volume":"19","author":"Morales","year":"1991","journal-title":"Urol Res"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.007_bib22","first-page":"1706","article-title":"Immunotherapy of an experimental adenocarcinoma of the prostate","volume":"153","author":"Morales","year":"1995","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.007_bib23","first-page":"1189","article-title":"Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer","volume":"156","author":"Chin","year":"1996","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.007_bib24","first-page":"1633","article-title":"Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder","volume":"166","author":"Morales","year":"2001","journal-title":"J\u00a0Urol"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.007_bib25","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1517\/13543784.10.12.2157","article-title":"Therapeutic potential of mycobacterial cell wall-DNA complexes","volume":"10","author":"Filion","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.007_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bjc.6690038","article-title":"Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells","volume":"79","author":"Filion","year":"1999","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.007_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s002620000121","article-title":"Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex","volume":"49","author":"Filion","year":"2000","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.007_bib28","first-page":"1040","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed","volume":"181","author":"Morales","year":"2009","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.007_bib29","first-page":"1135","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2015","journal-title":"J\u00a0Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:38:03Z","timestamp":1758807483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014319300850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0094014319300850"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.007","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage Therapy Using Bacillus Calmette-Gu\u00e9rin Derivatives or Single Agent Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}